会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Anti-fibril peptides
    • 抗原纤维肽
    • US07345022B2
    • 2008-03-18
    • US10666095
    • 2003-09-18
    • Robert P. HammerYanwen FuTod J. MillerMark L. McLaughlin
    • Robert P. HammerYanwen FuTod J. MillerMark L. McLaughlin
    • A61K38/03A61K38/08A61K38/10C07K4/00C07K7/06C07K7/08
    • C07K7/06A61K38/00C07K5/0806C07K5/1008C07K5/1019C07K7/08C07K14/4711
    • Novel peptides are disclosed that may be used as inhibitors of amyloidogenesis, as suppressors of amyloid toxicity, and as therapeutic agents for amyloid-associated diseases such as Alzheimer's disease, Parkinson's Disease, Creutzfeldt-Jakob Disease, Huntington's Disease, and Type II Diabetes. These new β-strand mimics (β-sheet “blockers”), containing Cα,α-disubstituted amino acids, specifically interact with and block the development of the β-sheet structure of the developing fibrils of amyloid diseases, such as Alzheimer's disease amyloid β-peptide (Aβ). We have discovered that oligomerization of β-sheet structures, including those implicated in amyloid-associated diseases, may be inhibited or even reversed by the presence of extended peptide structures that have only one edge available for hydrogen bonding. Without a second edge that is also available for hydrogen bonding, the extension of a developing β-sheet is blocked by binding to the novel peptides.
    • 公开了可用作淀粉样蛋白发生抑制剂的新型肽,作为淀粉样蛋白毒性的抑制剂,以及作为淀粉样蛋白相关疾病如阿尔茨海默氏病,帕金森氏病,克雅氏病,亨廷顿氏病和II型糖尿病的治疗剂。 这些新的β链模拟物(β-片段“阻断剂”),含有Cα,α - 二取代的氨基酸,特异性地相互作用并阻断了发展中的原纤维的β-折叠结构 淀粉样蛋白疾病,如阿尔茨海默病淀粉样蛋白β-肽(Abeta)。 我们已经发现,β-片结构的低聚,包括涉及淀粉样蛋白相关疾病的那些,可能被抑制或甚至被仅具有一个可用于氢键的边缘的延伸肽结构的存在所逆转。 没有可用于氢键的第二边缘,通过与新肽的结合阻断了显影的β-折叠片的延伸。